Sector News

New GSK chairman backs CEO Witty to stay at helm

May 8, 2015
Life sciences
GlaxoSmithKline’s new chairman Philip Hampton has thrown his support behind the company’s current structure and chief executive despite pressure from some shareholders for a change.
 
In his first comments since becoming chairman at the conclusion of the drugmaker’s annual meeting on Thursday, Hampton told reporters he hoped that CEO Andrew Witty would continue to run GSK for a good length of time.
 
“Andrew has the complete support of the board. There are always shareholders who have points to make, but I certainly hope Andrew is here for a good while to come,” Hampton said.
 
He said there is no “hard and fast rule” about how long chief executives should serve.
 
Yet Hampton, also chairman of the Royal Bank of Scotland (RBS.L), said there is an issue about GSK’s relative performance in terms of shareholder returns.
 
“We haven’t kept up with some of the better-performing companies,” he said.
 
GSK shares have underperformed the European drugs sector .SXDP by 23 percent in the past year.
 
Hampton joined GSK’s board only after the company agreed a $20 billion-plus asset swap with Novartis (NOVN.VX) last year but said he “likes the mix now”.
 
POTENTIAL BREAK-UP?
 
Asked about the potential for a future break-up of GSK and spin-off of its consumer health division, Hampton said it was not obvious that such a move was warranted.
 
“To me, it isn’t a screaming case that this is a useless conglomerate that needs to be broken up,” he said. “There are absolutely good arguments for that (consumer) business to fit well with large pharma.”
 
Hampton said he was closely involved in Wednesday’s strategy presentation showcasing GSK’s new structure after the Novartis deal, particularly on the issue of protecting the company’s dividend for three years.
 
GSK’s 5 percent dividend yield is a major lure for investors, but several years of stagnant sales growth and stalling demand for its market-leading lung drugs have stretched its payout capacity.
 
Hampton said it is important to rebuild dividend cover, which would be done in part by the decision to scale back a planned one-off cash return to investors this year.
 
GSK is banking on consumer health and vaccines to help to deliver reliable long-term growth, while it is more wary than rivals about the ability of drugmakers to sustain current high prices for prescription drugs.
 
Hampton said this cautious stance made sense, given that current high valuations for early-stage drugs are viewed by many people as “a bit of a pharma market bubble”.
 
(Reporting by Ben Hirschler; Writing by Martinne Geller; Editing by David Goodman and David Evans)
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach